Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) rece...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Clinical investigation
2022-04-01
|
| Series: | JCI Insight |
| Subjects: | |
| Online Access: | https://doi.org/10.1172/jci.insight.157031 |
| _version_ | 1818242331850047488 |
|---|---|
| author | Ane Ogbe Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater |
| author_facet | Ane Ogbe Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater |
| author_sort | Ane Ogbe |
| collection | DOAJ |
| description | Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. |
| first_indexed | 2024-12-12T13:43:32Z |
| format | Article |
| id | doaj.art-446dfee8ec4944f5951afc9fd4bc0066 |
| institution | Directory Open Access Journal |
| issn | 2379-3708 |
| language | English |
| last_indexed | 2024-12-12T13:43:32Z |
| publishDate | 2022-04-01 |
| publisher | American Society for Clinical investigation |
| record_format | Article |
| series | JCI Insight |
| spelling | doaj.art-446dfee8ec4944f5951afc9fd4bc00662022-12-22T00:22:45ZengAmerican Society for Clinical investigationJCI Insight2379-37082022-04-0177Durability of ChAdOx1 nCoV-19 vaccination in people living with HIVAne OgbeMatthew PaceMustapha BittayeTimothy TipoeSandra AdeleJasmini AlagaratnamParvinder K. AleyM. Azim AnsariAnna BaraSamantha BroadheadAnthony BrownHelen BrownFederica CappucciniPaola CinardoWanwisa DejnirattisaiKatie J. EwerHenry FokPedro M. FolegattiJamie FowlerLeila GodfreyAnna L. GoodmanBethany JacksonDaniel JenkinMathew JonesStephanie LongetRebecca A. MakinsonNatalie G. MarchevskyMoncy MathewAndrea MazzellaYama F. MujadidiLucia ParoliniClaire PetersenEmma PlestedKatrina M. PollockThurkka RajeswaranMaheshi N. RamasamySarah RheadHannah RobinsonNicola RobinsonHelen SandersSonia SerranoTom TiptonAnele WatersPanagiota ZacharopoulouEleanor BarnesSusanna DunachiePhilip GoulderPaul KlenermanGavin R. ScreatonAlan WinstonAdrian V.S. HillSarah C. GilbertMiles CarrollAndrew J. PollardSarah FidlerJulie FoxTeresa LambeJohn FraterDuration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.https://doi.org/10.1172/jci.insight.157031AIDS/HIVCOVID-19 |
| spellingShingle | Ane Ogbe Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV JCI Insight AIDS/HIV COVID-19 |
| title | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
| title_full | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
| title_fullStr | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
| title_full_unstemmed | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
| title_short | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
| title_sort | durability of chadox1 ncov 19 vaccination in people living with hiv |
| topic | AIDS/HIV COVID-19 |
| url | https://doi.org/10.1172/jci.insight.157031 |
| work_keys_str_mv | AT aneogbe durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT matthewpace durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT mustaphabittaye durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT timothytipoe durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT sandraadele durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT jasminialagaratnam durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT parvinderkaley durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT mazimansari durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT annabara durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT samanthabroadhead durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT anthonybrown durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT helenbrown durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT federicacappuccini durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT paolacinardo durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT wanwisadejnirattisai durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT katiejewer durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT henryfok durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT pedromfolegatti durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT jamiefowler durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT leilagodfrey durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT annalgoodman durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT bethanyjackson durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT danieljenkin durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT mathewjones durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT stephanielonget durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT rebeccaamakinson durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT nataliegmarchevsky durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT moncymathew durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT andreamazzella durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT yamafmujadidi durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT luciaparolini durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT clairepetersen durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT emmaplested durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT katrinampollock durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT thurkkarajeswaran durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT maheshinramasamy durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT sarahrhead durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT hannahrobinson durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT nicolarobinson durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT helensanders durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT soniaserrano durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT tomtipton durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT anelewaters durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT panagiotazacharopoulou durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT eleanorbarnes durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT susannadunachie durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT philipgoulder durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT paulklenerman durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT gavinrscreaton durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT alanwinston durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT adrianvshill durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT sarahcgilbert durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT milescarroll durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT andrewjpollard durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT sarahfidler durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT juliefox durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT teresalambe durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT johnfrater durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv |